专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

US20110091376A1 CATATONIC STEROID ANTIMICROBIAL DIAGNOSTIC, DETECTION, SCREENING AND IMAGING METHODS 有权
标题翻译： CATATONIC STEROID抗微生物诊断，检测，筛选和成像方法
公开(公告)号：US20110091376A1
公开(公告)日：2011-04-21
申请号：US13000010
申请日：2009-06-16
申请人： Paul B. Savage
发明人： Paul B. Savage
IPC分类号： A61K51/04 , A61K49/00 , A61K49/10 , A61K49/04 , C12Q1/70 , C12Q1/04
CPC分类号： A61K51/0493
摘要： The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA-13 labeled with 99mTc is used to detect the presence of an infection.
摘要翻译：本发明涉及诊断，检测，筛选和成像方法。在各种实施方案中，诊断，检测，筛选和成像的方法包括向具有感染或过度增殖性疾病（例如肿瘤，癌症或瘤形成）的风险的受试者施用阳离子类固醇抗微生物剂或CSA，其量有效诊断或检测受试者中的感染或过度增殖性疾病（例如肿瘤，癌症或瘤形成）。在特定方面，可检测的CSA，即用99mTc标记的CSA-13用于检测感染的存在。

92. 发明授权

US07598234B2 Steroid derived antibiotics 有权
公开(公告)号：US07598234B2
公开(公告)日：2009-10-06
申请号：US10892828
申请日：2004-07-16
申请人： Paul B. Savage , Chunhong Li
发明人： Paul B. Savage , Chunhong Li
IPC分类号： A61K31/56
CPC分类号： C07J41/0055
摘要： A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.

93. 发明授权

US06767904B2 Steroid derived antibiotics 有权
标题翻译：类固醇衍生的抗生素
公开(公告)号：US06767904B2
公开(公告)日：2004-07-27
申请号：US09930316
申请日：2001-08-15
申请人： Paul B. Savage , Chunhong Li
发明人： Paul B. Savage , Chunhong Li
IPC分类号： A61K3156
CPC分类号： C07J41/0055
摘要： A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.
摘要翻译：描述了一系列新型类固醇衍生物。类固醇衍生物是抗菌剂。类固醇衍生物还用于使细菌对其他抗生素（包括红霉素和新生霉素）敏感。

94. 发明授权

US10676501B2 Hydrogel materials incorporating eluting ceragenin compound 有权
公开(公告)号：US10676501B2
公开(公告)日：2020-06-09
申请号：US13554930
申请日：2012-07-20
申请人： Paul B. Savage
发明人： Paul B. Savage
IPC分类号： A61L27/14 , C07J41/00 , A61L27/52 , A61L27/54 , A61L31/14 , A61L31/16 , A61L27/34 , A61L29/08 , A61L29/14 , A61L29/16 , A61L31/10 , C07C211/00 , A61L27/18 , A61L29/04 , A61L31/04
摘要： A hydrogel polymer includes a ceragenin compound. The ceragenin compound has a hydrophobicity/hydrophilicity that produces a release rate in a range of 0.1-100 μg/ml for at least 3 days.

95. 发明申请

US20180280550A1 CATIONIC STEROID ANTIMICROBIAL DIAGNOSTIC, DETECTION, SCREENING AND IMAGING METHODS 审中-公开
公开(公告)号：US20180280550A1
公开(公告)日：2018-10-04
申请号：US15934534
申请日：2018-03-23
申请人： Paul B. Savage
发明人： Paul B. Savage
IPC分类号： A61K51/04
摘要： The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA-13 labeled with 99mTc is used to detect the presence of an infection.

96. 发明申请

US20160311852A1 METHODS FOR THE SYNTHESIS OF CERAGENINS 有权
标题翻译：合成谷蛋白的方法
公开(公告)号：US20160311852A1
公开(公告)日：2016-10-27
申请号：US15135900
申请日：2016-04-22
申请人： Paul B. Savage , Jared Lynn Randall
发明人： Paul B. Savage , Jared Lynn Randall
IPC分类号： C07J75/00 , C07J41/00
CPC分类号： C07J75/00 , C07J9/005 , C07J41/0055 , C07J41/0061 , C07J41/0066 , C07J41/0088 , C07J41/0094 , C07J51/00
摘要： Disclosed herein are methods of making ceragnenin compounds for treating, preventing, or diagnosing diseases, disorders, or conditions associated with bacterial or viral infections, cancer, inflammation, and osteogenesis. Ceragenin compounds display broad-spectrum antibacterial activity utilizing a mode of action similar to antimicrobial peptides, but without the high synthesis costs and susceptibility to proteolytic degradation. Ceragenin compounds reproduce the amphiphilic morphology found in many antimicrobial peptides and display potent and diverse biological activities, including anti-bacterial, anti-cancer, anti-inflammatory, bone growth promotion, and wound healing promotion.
摘要翻译：本文公开了制备用于治疗，预防或诊断与细菌或病毒感染，癌症，炎症和成骨相关的疾病，病症或病症的角质层蛋白化合物的方法。 Ceragenin化合物利用类似于抗微生物肽的作用模式显示广谱抗菌活性，但没有高的合成成本和对蛋白水解降解的易感性。 Ceragenin化合物再现许多抗微生物肽中发现的两亲形态，并显示出有效和多样化的生物活性，包括抗菌，抗癌，抗炎，骨生长促进和伤口愈合促进。

97. 发明申请

US20160193232A1 TREATMENT AND PREVENTION OF MASTITIS 审中-公开
标题翻译：治疗与防治主体
公开(公告)号：US20160193232A1
公开(公告)日：2016-07-07
申请号：US15070845
申请日：2016-03-15
申请人： Chad S. Beus , Paul B. Savage
发明人： Chad S. Beus , Paul B. Savage
IPC分类号： A61K31/575 , A61K9/00
CPC分类号： A61K31/575 , A61K9/0041
摘要： Treating and/or preventing clinical mastitis includes administering a cationic steroidal anti-microbial (CSA) formulation to the intra-mammary organ of a mammal (e.g., a dairy cow), such as by injection into the mammary organ and/or topical application. The CSA formulation can be effective in treating and/or preventing mastitis caused by gram positive bacteria, gram negative bacteria, fungus, and/or prototheca. The dairy cow can be lactating and have a somatic cell count (SCC) less than or equal to 500,000 cells/mL at the time of administering the CSA formulation. Alternatively, the dairy cow can be lactating and have a somatic cell count (SCC) greater than 500,000 cells/mL at the time of administering the CSA formulation. The dairy cow can be taken out of production during the administration of the CSA formulation for a period of time of about 3 days or less, 2 days or less, or 1 day or less.
摘要翻译：治疗和/或预防临床乳腺炎包括向哺乳动物（例如，奶牛）的乳腺内器官施用阳离子类甾体抗微生物（CSA）制剂，例如通过注射到乳腺器官和/或局部应用中。 CSA制剂可有效治疗和/或预防革兰氏阳性细菌，革兰氏阴性细菌，真菌和/或原虫引起的乳腺炎。在施用CSA制剂时，奶牛可以是泌乳的并且具有小于或等于500,000细胞/ mL的体细胞计数（SCC）。或者，在施用CSA制剂时，奶牛可以是泌乳的并且具有大于500,000个细胞/ mL的体细胞计数（SCC）。在CSA制剂的给药期间，奶牛可以在约3天或更少，2天或更少或1天或更少的时间内被取出生产。

98. 发明授权

US09295722B2 Bacterial glycolipid activation of CD1d-restricted NKT cells 有权
标题翻译：细胞糖脂激活CD1d限制性NKT细胞
公开(公告)号：US09295722B2
公开(公告)日：2016-03-29
申请号：US11814103
申请日：2006-01-26
申请人： Paul B. Savage , Albert Bendelac , Luc Teyton
发明人： Paul B. Savage , Albert Bendelac , Luc Teyton
IPC分类号： A61K39/00 , C07H17/02 , A61K31/70 , A61K31/74 , A61K39/39 , A61K31/7032 , A61K35/74 , A61K38/17
CPC分类号： A61K39/39 , A61K31/7032 , A61K35/74 , A61K38/1774 , A61K2039/55594 , Y02A50/403
摘要： Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting an NKT cell with a bacterial glycolipid complexed with a CD1 molecule to activate the NKT cell. The bacterial glycolipid may be derived from a member of the Class Alphaproteobacteria.
摘要翻译：公开了用于激活NKT细胞的方法，刺激受试者的免疫应答的方法，改善疫苗功效的方法以及治疗感染的方法。还公开了促进肿瘤排斥，治疗癌症，调节自身免疫并抑制受试者中变应原诱导的超敏反应的方法。所述方法包括使NKT细胞与与CD1分子复合的细菌糖脂接触以激活NKT细胞。细菌糖脂可以衍生自阿尔法糖酵母属的成员。

99. 发明申请

US20160052959A1 RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND DIAGNOSTIC METHODS 审中-公开
标题翻译：放射性阳离子甾体抗生素和诊断方法
公开(公告)号：US20160052959A1
公开(公告)日：2016-02-25
申请号：US14830356
申请日：2015-08-19
申请人： Paul B. Savage
发明人： Paul B. Savage
IPC分类号： C07J43/00 , G01N33/534 , G01N33/58 , A61K51/04 , C07J51/00
CPC分类号： C07J43/003 , A61K51/0493 , C07J41/0088 , G01N33/534 , G01N33/56911 , G01N33/56983
摘要： The disclosure provides compounds, methods, and kits for diagnosis, detection, screening, and imaging of a disease condition (e.g., infection, cancer, tumor, neoplasia), in vitro, ex vivo, and/or in vivo. Certain embodiments include administering a cationic steroid antimicrobial “CSA” or “ceragenin”), the CSA including a steroidal backbone and a heterocyclic ring separated from the steroidal backbone by at least 4 atoms (and up to 24 atoms or more), to a subject having or at risk of having a disease condition in an amount effective to diagnose, detect, screen for or image the disease condition in the subject.
摘要翻译：本公开提供了在体外，离体和/或体内诊断，检测，筛选和成像疾病状况（例如，感染，癌症，肿瘤，瘤形成）的化合物，方法和试剂盒。某些实施方案包括施用阳离子类固醇抗微生物“CSA”或“ceragenin”），CSA包括甾族主链和从甾体骨架分离至少4个原子（至多24个原子或更多））到受试者的杂环具有或具有有效诊断，检测，筛选或成像受试者的疾病状况的疾病状况的风险。

100. 发明授权

US08945217B2 Medical devices incorporating ceragenin-containing composites 有权
标题翻译：包含含Ceragenin的复合材料的医疗器械
公开(公告)号：US08945217B2
公开(公告)日：2015-02-03
申请号：US13594612
申请日：2012-08-24
申请人： Paul B. Savage , Roy D. Bloebaum , Dustin L. Williams , Kristofer D. Sinclair , Bryan S. Haymond
发明人： Paul B. Savage , Roy D. Bloebaum , Dustin L. Williams , Kristofer D. Sinclair , Bryan S. Haymond
IPC分类号： A61F2/02 , A01N45/00 , A01N25/10 , A61L27/34 , A61L27/54
CPC分类号： A01N45/00 , A01N25/10 , A61F2/02 , A61L27/34 , A61L27/54 , A61L2300/404
摘要： A medical device that includes a coating of a composite material that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 μm, 50 nm to 10 μm, 100 nm to 5 Ξm, or 1 μm to 10 μm. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.
摘要翻译：一种医疗装置，其包括复合材料的涂层，所述复合材料的涂层包括具有空隙结构的聚合物材料和与所述空隙结构相关联的颗粒状氧化铈颗粒（即，ceragenin颗粒）。复合材料中的表面活性剂颗粒的平均粒径在5nm〜20μm，50nm〜10μm，100nm〜5＆amp; Xgr，m或1μm〜10μm的范围内。该复合材料具有高负载量的ceragenin颗粒（例如，约10重量％至约25重量％）。该复合材料具有良好的聚合物稳定性，以特征洗脱速率在持续的时间内从配置在复合材料中的ceragenin颗粒释放ceragenins的能力，以及在持续时间内杀死大量细菌和其他易感微生物的能力时间。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式